Treatment for Arrhythmias, Cardiac

Phase-Based Progress Estimates
University of Texas Medical Branch, Galveston, TX
Arrhythmias, Cardiac+1 More
All Sexes
What conditions do you have?

Study Summary

The study will involve exposing individuals with a known past medical history of diabetes mellitus and/or cardiac arrhythmias to centrifuge-induced acceleration force (G-force) in the NASTAR AFTS-400 simulator to evaluate their response to such forces. Subjects without a history of these conditions will also undergo centrifuge-induced G-forces as controls. This study will contribute to the knowledge of how individuals with such medical conditions experience G-forces that may be experienced during commercial spaceflights.

Eligible Conditions

  • Arrhythmias, Cardiac
  • Diabetes Mellitus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Arrhythmias, Cardiac

Study Objectives

9 Primary · 0 Secondary · Reporting Duration: up to 12 min, assessed during the duration of acceleration exposure

5 minutes after centrifuge profile
Diastolic Blood Pressure - after
5 minutes before centrifuge profile
Diastolic Blood Pressure - before
Systolic Blood Pressure - after
Systolic Blood Pressure - before
5 seconds after the onset of acceleration
Heart Rate
approximately 1 min, immediately following final acceleration profile
Errors during Emergency Scenario
Time of data entry completion during Emergency Scenario
Hour 8
Blood Glucose
up to 12 min, assessed during the duration of acceleration exposure
ECG dysrthythmias

Trial Safety

Safety Progress

1 of 3

Other trials for Arrhythmias, Cardiac

Trial Design

0 Treatment Group

60 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 min, assessed during the duration of acceleration exposure
Closest Location: University of Texas Medical Branch · Galveston, TX
Photo of texas 1Photo of texas 2Photo of texas 3
2011First Recorded Clinical Trial
2 TrialsResearching Arrhythmias, Cardiac
323 CompletedClinical Trials

Who is running the clinical trial?

Civil Aerospace Medical InstituteFED
2 Previous Clinical Trials
284 Total Patients Enrolled
The University of Texas Medical Branch, GalvestonLead Sponsor
220 Previous Clinical Trials
55,053 Total Patients Enrolled
William Powers, MDPrincipal InvestigatorUniversity of Texas Medical Branch at Galveston

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have well-controlled diabetes mellitus (Type I or Type II, controlled with diet, oral medications, or insulin injections or pump) with an HbA1c of <8% or well-controlled cardiac arrhythmias (including control via oral medications, implanted pacemakers, prior ablation or similar intervention).
Subjects with a history of both diabetes mellitus and cardiac arrhythmia are considered eligible for inclusion if both diseases meet inclusion criteria.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.